Prospective analyses of immunne response to establish of predictive biomarker of anti-cancer immunotherapies effect in solid tumor

Prospective analyses of immunne response to establish of predictive biomarker of anti-cancer immunotherapies effect in solid tumor - Prospective analyses of immunne response to establish of predictive biomarker of anti-cancer immunotherapies effect in solid tumor

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027413

Enrollment

400

Registered

2017-05-22

Start date

2016-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically confirmed diagnosis of solid tumor (aged 20 years or older) 2. Immune checkpoint inhibitors treatment are planned 3. Biopsy of tumor tissue is planned for diagnoses 4. Drawing 30mL peripheral blood is considered proper

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To establish of predictive biomarker of anti-cancer immunotherapies effect in solid tumor	—

Countries

Japan

Contacts

Public ContactShohei Koyama

National Cancer Center Hospital East Division of Cancer Immunology

esugiyam@east.ncc.go.jp0471331111

Outcome results